Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) shares rose 9.7% during mid-day trading on Thursday . The company traded as high as $13.39 and last traded at $13.44. Approximately 455,832 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 1,298,486 shares. The stock had previously closed at $12.25.
Ginkgo Bioworks Stock Performance
The stock’s 50 day moving average price is $10.35. The company has a market capitalization of $767.07 million, a PE ratio of -1.02 and a beta of 1.09.
Institutional Trading of Ginkgo Bioworks
Several institutional investors have recently modified their holdings of the company. KBC Group NV bought a new position in shares of Ginkgo Bioworks in the fourth quarter valued at $31,000. Palumbo Wealth Management LLC acquired a new position in shares of Ginkgo Bioworks in the 4th quarter valued at $144,000. SG Americas Securities LLC purchased a new position in Ginkgo Bioworks in the 4th quarter worth about $199,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in Ginkgo Bioworks by 644.5% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company’s stock worth $263,000 after buying an additional 27,978 shares during the period. Finally, FNY Investment Advisers LLC lifted its stake in Ginkgo Bioworks by 125.6% during the fourth quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company’s stock valued at $745,000 after buying an additional 42,298 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Articles
- Five stocks we like better than Ginkgo Bioworks
- Learn Technical Analysis Skills to Master the Stock Market
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- 3 Warren Buffett Stocks to Buy Now
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- How to Use the MarketBeat Dividend Calculator
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.